180340-58-3Relevant articles and documents
COMPOUNDS
-
Page/Page column 35, (2017/11/04)
There are provided 5,6-dihydro-4H-dithieno[3,2-b:2',3'-d]azepine derivatives(as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.
The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-Aroyl-2,4,5,6-tetrahydropyrazolo-[3,4-d]thieno[3,2-b]azepines
Albright, J. Donald,Santos, Efren G. Delos,Dusza, John P.,Chan, Peter S.,Coupet, Joseph,Ru, Xun,Mazandarani
, p. 695 - 698 (2007/10/03)
Synthesis and SAR of N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(2H)-yl)carbonyl]phenyl]be nzamides as arginine vasopressin (AVP) receptor antagonists are discussed. Potent orally active AVP receptor antagonists are produced when the benzamide moiety contains a phenyl group at the 2-position. Similar analogues of 4,6,7,8-tetrahydro-5H-thieno[3,2-b]azepine and VPA-985 are reported. (C) 2000 Elsevier Science Ltd. All rights reserved.
TRICYCLIC THIENO-AZEPINE VASOPRESSIN ANTAGONISTS
-
, (2008/06/13)
This invention relates to new bicyclic non-peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.